tbuckley/cabot-search huggingface dataset:
The association of 5FU-based chemotherapy with pathological response or survival compared to carbo/taxol with locally advanced resectable esophageal cancer.
Authors: Mohammed Al-Jumayli, Saqib Abbasi, Anup Kasi, Anwaar Saeed
Journal: Journal of Clinical Oncology (2019)

165 Background: Neoadjuvant chemoradiation followed by esophagectomy is the standard of care in advanced EC. While 5FU based chemoradiation has been a common regimen in the past, its utilization has declined in recent years as the CROSS trial study regimen of carboplatin/paclitaxel has become widely adopted. A prospective evaluation of the CROSS regimen compared to the 5FU based regimen was never performed. The aim of this study is to report our institutional experience with these two chemotherapy regimens. To the best of our knowledge, this is the largest retrospective study comparing the two types of chemotherapy regimens. Methods: We performed an IRB-approved retrospective review of a prospectively maintained institutional cancer registry. EC patients who completed trimodality therapy with either carboplatin/paclitaxel or 5FU/platinum were identified and divided into groups based on their chemotherapy regimens. Multivariable logistic regression was used to analyze pathologic complete response (pCR) rates, while the Kaplan–Meier and Cox proportional hazards models were utilized to evaluate DFS and OS. Analytical models were adjusted for age, stage, radiation dose, histology sub-type, and time interval from completion of neoadjuvant therapy to surgery. Results: 224 patients treated between January of 2007 and July of 2017 were identified . Of this group, 139(62%) had received Carbo/Taxol, while 85 (37%) had received 5FU/platinum. There was no increase in the odds of pCR with 5FU based chemo compared to CROSS regimen (OR = 2.68, P = 0.671). Furthermore, the OS and DFS of 159 patients(80 5FU/platinum, 77 carbo/taxol) with median follow up of ~ 5 yrs were not statistically different with HR 1.08 (0.6-1.7) and P value 0.71. Conclusions: Neoadjuvant chemoradiation with 5FU/platinum in resectable EC is not associated with higher rates of pCR, DFS and OS compared to the CROSS regimen of carbo/taxol. Those findings will need to be validated in a larger cohort.
Abstract 12089: Risk Factors for Major Complications in the Implantation of Epicardial Pacemakers in Neonates and Infants
Authors: Ahmad S Chaouki
Journal: Circulation (2015)

Introduction: Complications related to epicardial cardiac rhythm devices in infants have been reported though limited data are available regarding their incidence and associated risk factors. Hypothesis: Epicardial pacemakers carry a risk for significant complications which is associated with patient and device characteristics. Methods: Retrospective study of all patients at a single center receiving an epicardial pacemaker at ≤12 months of age at time of implant. Patient characteristics: weight, length, BSA, reason for implantation, prematurity, congenital heart disease and concomitant surgery were obtained. Device characteristics: height, width, length, thickness, mass and volume were also obtained. Wilcoxon Rank-Sum and Fisher’s exact tests were used to compare patient and device characteristics with and without major complications (any re-admission after implant). Using identified characteristics associated with complication, pre-implantation cutoffs for high and low risk for complications were established. Results: Eighty-six patients were identified, age 73 d (IQR 13-166); 12 (14%) had a major complication, 7 (8%) needed surgical intervention (6 for wound dehiscence and 1 for pericardial effusion) and 3 (3%) required whole system explantation. Younger age (9 vs 89 d, p=0.01), lower weight (2.91 vs 4.44 kg, p=0.004) and lower BSA (0.19 vs 0.24 m 2 , p=0.03) were associated with major complications. Other patient characteristics were not statistically different. Device height, thickness, mass, volume and dual vs. single chamber system did not differ between groups; however device width differed in patients with complications (p=0.02). Based on these data, a cutoff of &gt;3 kg and ≥ 6 days of age was established as lower risk. Patients with weight ≤ 3 kg and/or &lt;6 days old had an OR of 18.1 (3.6-91.2, p&lt;0.001) for developing a major complication. Using this model resulted in a sensitivity of 83% and positive and negative predictive values of 38% and 97%, respectively. Conclusions: Young age and low weight at the time of implant are risk factors for major complications while device characteristics appear to play a minor role. Using weight and age cutoffs of 3 kg and 6 days respectively may predict patients at very low risk for developing major complications.
A Decade of Health Information Technology Usability Challenges and the Path Forward
Authors: Raj M. Ratwani, Jacob Reider, Hardeep Singh
Journal: JAMA (2019)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Sleeve gastrectomy surgery reduces airway resistance and inflammation in chronically allergen-challenged obese mice
Authors: Mark Ihrie, Victoria McQuade, Akhil Hegde, Jingjing Niu, Jenny Tong, David D'Alessio, Julia K.L. Walker, Loretta G. Que, Jennifer L. Ingram
Journal: Journal of Allergy and Clinical Immunology (2019)

RATIONALE: Obesity increases asthma severity.Weight loss in bariatric surgery improves asthma symptoms and reduces airway hyperresponsiveness.We hypothesized that vertical sleeve gastrectomy (VSG), a model of bariatric surgery, would reduce airway pathology in allergen-challenged obese mice.METHODS: Five-week old C57BL6 mice were fed a high fat diet (HFD -45% kcal fat) or normal chow and concurrently challenged with intranasal house dust mite (HDM) allergen (25 mg) or saline 3 days/week for 8 weeks.These challenged mice immediately underwent VSG or sham surgery, or no surgery (NS) as control (n55 per group).After one-week recovery, mice were returned to HFD and HDM challenges for four weeks.Twenty-four hours after the final HDM challenge, the mice were tested for airway responsiveness to increasing doses of methacholine delivered intravenously, and lung mechanics were evaluated using Flexivent (SciReq).Blood and bronchoalveolar lavage (BAL) with saline were collected.Harvested lung slices were stained with Masson's trichrome, Periodic acid Schiff or hematoxylin and eosin stains.Percent trichrome staining was quantified using Image J (NIH).Interleukin (IL)-13, IL-5, glucagon-like peptide-1, transforming growth factor-beta, insulin and leptin were measured in blood and/or lavage fluid using ELISA.RESULTS: VSG induced significant weight loss and reduction of plasma leptin levels (p<0.05).Airway reactivity to bronchoconstrictor, airway tissue inflammation and percent BAL eosinophils (13.3% NS, 4.7% sham, 0.8% VSG) were reduced in HFD-fed, HDM-challenged mice following VSG compared to sham or NS (p<0.05).CONCLUSIONS: Weight loss surgery in obese, chronically allergenchallenged mice induces metabolic changes associated with improved airway inflammation and resistance.
Place based rivalry is instilled when you decide to apply to medical school
Authors: Angelica Sharma, Arun Sharma
Journal: BMJ (2019)

Place based rivalry is important and relevant.1 It is instilled before beginning the path to becoming a doctor. An important decision is which medical school entrance examination to sit. From this decision, a clear divide exists between those applying to Oxford, Cambridge, or London and those applying elsewhere. Those applying to Oxford, Cambridge, or London are presumed to be superhuman, when we are all equally …
Abstract 14950: A Precision Medicine Blood Test Incorporating Age, Sex, and Gene Expression Showed Clinical Utility in the Evaluation of Outpatients Presenting With Stable Symptoms Suggestive of Obstructive Coronary Artery Disease - Final Endpoint Analysis From the PRESET Registry
Authors: Joseph Ladapo, Matthew Budoff, David Sharp, Michael Zapien, Lin Huang, Bruce Maniet, Lee Herman, Mark Monane
Journal: Circulation (2016)

Introduction: More effective tactics are needed to evaluate symptomatic patients with suspected obstructive coronary artery disease (CAD) in the outpatient setting, as current conventional methods ...
THROMBOTIC THROMBOCYTOPENIC PURPURA
Journal: JAMA (1962)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Characterization of CAT-8015: A Pseudomonas exotoxin based immunotoxin for the treatment of CD22-related hematological malignancies
Authors: Ralph F. Alderson, Enrique Escandon, Tianling Chen, Peter Yeung, Douglas Hodges, Wei Geng, David J P Fitzgerald, Robert J. Kreitman, Ira Pastan, Judy A. Fox
Journal: Cancer Research (2006)

3728  Immunotoxins are a class of anti-cancer therapies that are hybrid proteins composed of a tumor-targeting monoclonal antibody and a cell-killing toxin moiety. CAT-8015 (formerly HA22) is a second generation immunotoxin consisting of disulfide bond stabilized Fv fragments of RFB4, an anti-CD22 monoclonal antibody, and the translocating and ADP-ribosylating domains of Pseudomonas exotoxin A (PE38). The biological activity of CAT-8015 was examined in vitro on the EHEB, CA46, Mec1, Daudi and JD38 B-cell lines using two different cytotoxicity assays; a cell viability-based assay and an inhibition of protein synthesis-based assay. The range of IC50s in both assays for the various cell lines was 0.1 - 10 ng/ml. Time course studies demonstrated that exposure to the immunotoxin for as little as 4 hr was sufficient to induce a significant amount of cell killing. Pharmacokinetic studies with CAT-8015 were conducted in mice, rats and cynomolgus monkeys and the data were analyzed using a compartmental model. The t1/2 values were calculated to be 0.42, 0.61 and 0.78 hr and the Vss values were 1.37, 10.6 and 123.1 ml in mice, rats and monkeys, respectively. The in vivo anti-tumor activity of CAT-8015 was examined in a subcutaneous tumor model using the CD22-expressing Burkitt’s lymphoma cell line JD38. When the average tumor volume reached 100-200 mm3, increasing doses of the immunotoxin were administered intravenously at 48 hr intervals for a total of three doses. Treatment with 12.5 μg/kg resulted in a cytostatic response. At higher doses, ≥ 25 μg/kg, a rapid reduction in tumor volume occurred that reached a nadir within 7 days, and complete remissions were achieved with doses ≥ 75 μg/kg. In additional experiments, rapid shrinkage of larger tumors, up to approximately 800 mm3, was also achieved following CAT-8015 administration. In contrast, CAT-3888 (formerly BL22) administration induced a cytostatic response even at doses as high as 150 μg/kg and a rebound in tumor growth was observed within 2 - 3 weeks at all the doses tested. As an additional comparison, animals bearing JD38 tumors were administered rituximab every four days for 3 doses. Treatment with rituximab at doses as high as 5 mg/kg resulted in only a transitory inhibition of tumor growth. In summary, CAT-8015 is a highly efficacious CD22-directed immunotoxin that induced complete remission of tumors in a mouse xenograft lymphoma model at doses that were well tolerated by the mice.
Influence of Minimal Residual Disease on Survival of Patients with Mantle Cell Lymphoma
Authors: Mariia Mikhaleva, Alexey Kuvshinov, Alexander Schmidt, Vasily Shuvaev, Karina Krutikova, Elena Belyakova, Irina Martynkevich, Alexander Chechetkin, Sergei Voloshin
Journal: Blood (2018)
Three-Year Observation of Children 3 to 10 Years of Age with Untreated Intermittent Exotropia
Authors: Brian G. Mohney, Susan A. Cotter, Danielle L. Chandler, Jonathan M. Holmes, David K. Wallace, Tomohiko Yamada, David B. Petersen, Raymond T. Kraker, Christie L. Morse, B. Michele Melia, Rui Wu
Journal: Ophthalmology (2019)
Absence of NKG2D Ligands Defines Human Acute Myeloid Leukaemia Stem Cells and Mediates Their Immune Evasion
Authors: Anna M Paczulla, Kathrin Rothfelder, Simon Raffel, Martina Konantz, Julia Steinbacher, Hui Wang, Marcelle Ndoh Mbarga, Thorsten Schaefer, Daniela Dörfel, Mattia Falcone, Eva Nievergall, Claudia Tandler, Christoph Lutz, Pontus Lundberg, Lothar Kanz, Leticia Quintanilla-Martinez, Alexander Steinle, Andreas Trumpp, Helmut R. Salih, Claudia Lengerke
Journal: Blood (2018)
Identification of a Novel Heterozygous Mutation (c.2213T&gt;G;p.Leu738Arg) in Platelet Glycoprotein ITGB3 gene in a Patient with Glanzmann's Thrombasthenia
Authors: Candido E. Rivera, Prakash Vishnu, Gretchen Schaef Johns, Rajiv K. Pruthi, Dong Chen
Journal: Blood (2018)
PD-L1 Expression Is Low in Large B-Cell Lymphoma with MYC or Double-Hit Translocation
Authors: Mette Vestergaard Elbæk, Mette Ø Pedersen, Marie Fredslund Breinholt, Anupama Reddy, Cassandra Love, Erik Clasen-Linde, Helle Knudsen, Signe Ledou Nielsen, Anne Ortved Gang, Estrid Hogdall, Sandeep Dave, Peter H. Norgaard
Journal: Blood (2018)
Abstract 21362: The Combination Antiretroviral Therapy (cart) Inhibits Efferocytosis-Related Gene Expression via Activating P90rsk and Accelerates Atherosclerosis
Authors: Nhat Tu Le, Meera V. Singh, Kyung Ae Ko, Kyung-sun Heo, Yunting Tao, Jan Medina, Tamlyn Thomas, Nicole E. Stirpe, Wang Lu, Alicia Tyrell, Kathleen J. Gates, Xing Qui, Keigi Fujiwara, Sanjay B. Maggirwar, Giovanni Schifitto, Jun-ichi Abe
Journal: Circulation (2017)

Background: Increased incidence of cardiovascular disease (CVD) in HIV patients has been established, but the consequence of anti-HIV therapies in CVD is unclear. The activation of p90RSK in endothelial cells is a critical event in atherosclerosis, but its role in macrophage is unknown. Hypothesis: macrophage p90RSK plays a role in anti-HIV drug-induced CVD and atherosclerosis. Methods and Results: In macrophages, efferocytosis-related signaling was upregulated and inflammatory gene expression was down-regulated in a p90RSK activity-dependent manner. Using Lysm-Cre dominant negative (DN) p90RSK transgenic mice in LDLR -/- background fed a high-cholesterol diet, we found that p90RSK activation increases plaque formation, inducing pro-atherogenic phenotypes and enhancing M1 polarization. Every cART regimen we tested, except backbone regimen, activated macrophage p90RSK, reduced efferocytosis, and increased M1-type related gene expression. In human, peripheral monocytes were isolated from HIV infected individuals on stable cART for at least 1 year and with viral load ≤50 copies/mL and also from HIV negative and non-cART treated controls matched for age, gender, environment and Reynolds CVD risk score. We found significantly increased p90RSK activation in the cART-treated group, and additional treatment of low dose of H 2 O 2 (200 nM) accelerated p90RSK activation more in the macrophage isolated from cART-treated patients than those in control patients in vitro . Conclusions: Our results demonstrate that p90RSK is robustly activated by anti-HIV drug treatments known to be a high CVD risk. This activation culminates in reduced activity of macrophage efferocytosis, thereby accelerating atherosclerotic plaque formation. Monocyte/macrophage p90RSK can be a good target and an excellent biological marker to prevent and predict drugs-induced CVD.
Clinical features, predictors, and long‐term prognosis of pacing‐induced cardiomyopathy
Authors: Sung Woo Cho, Hye Bin Gwag, Jin Kyung Hwang, Kwang Jin Chun, Kyoung‐Min Park, Young Keun On, June Soo Kim, Seung‐Jung Park
Journal: European Journal of Heart Failure (2019)
Phase Ib study of talimogene laherparepvec (T-VEC) injection into liver metastases (LMs) in combination with intravenous (IV) atezolizumab in patients (pts) with metastatic triple-negative breast cancer (TNBC) or colorectal cancer (CRC).
Authors: J. Randolph Hecht, Arlene Chan, Miguel Martin, Nicolas Mach, Sara A. Hurvitz, Sylvie Rottey, Uwe Pelzer, Chunxu Liu, Emily Chan
Journal: Journal of Clinical Oncology (2019)

TPS725 Background: T-VEC is a genetically modified, oncolytic herpes simplex virus type 1 designed to selectively replicate within tumors and produce GM-CSF to enhance systemic antitumor immune responses. Atezolizumab is a monoclonal antibody checkpoint inhibitor (CPI) that targets PD-L1. The safety of intrahepatic administration of T-VEC has been demonstrated in a prior clinical trial (NCT02509507). A previous trial of T-VEC in combination with a CPI in advanced melanoma demonstrated improved responses compared to those with a CPI alone (Puzanov et al. JCO. 2016; 34:2619-26). We hypothesize that T-VEC combined with a CPI may also be effective in other tumor types. This phase 1b, multicenter study evaluates the safety of intrahepatic injection of T-VEC in combination with IV atezolizumab in pts with TNBC or CRC with LMs. Methods: The study will enroll up to 36 pts in two parallel cohorts (18 TNBC, 18 CRC) at sites in the USA, Europe, and Australia. The primary objective is to evaluate the incidence of dose-limiting toxicities (DLTs). Secondary objectives include objective response rate, lesion-level responses in injected and uninjected tumors, progression-free survival, and overall survival. Key eligibility criteria include age ≥ 18 years, confirmed diagnosis of TNBC or CRC with LMs, ECOG performance status 0/1, adequate organ function, disease progression during or after ≥ 1 prior standard-of-care systemic therapy for metastatic disease, and ≥ 1 measurable, injectable LM. T-VEC will be given by image-guided intralesional injection of up to 4 mL of 10 6 plaque forming units (PFU)/mL on day 1 and up to 4 mL of 10 8 PFU/mL every 21 days thereafter; atezolizumab 1,200 mg IV will be given on day 1 and every 21 days thereafter. The DLT-evaluation period is the first two cycles (1 cycle = 21 days). Interim safety analysis will occur after the first 4–6 pts have become DLT evaluable. Up to six cycles of T-VEC will be given with an additional 6 cycles allowed. After cycle three, nonhepatic lesions may be injected, subject to protocol-defined criteria. The study opened for enrollment in January 2018. (NCT03256344) Clinical trial information: NCT03256344.
Prognostic Value of Immunohistochemical Markers in Stage III/IV Classical Hodgkin Lymphoma Treated Frontline in the Lysa EORTC 20012 Randomized Protocol
Authors: Danielle Canioni, Pauline Brice, Serge Bologna, Laurent Voillat, Jean Gabarre, Olivier Casasnovas, Alain Devidas, Bertrand Coiffier, Malek Aoudjhane, Bruno Audhuy, Marc Andre, Catherine Fortpied, Patrice Carde, Nicolas Mounier, Josette Briere
Journal: Blood (2018)
Broken necks in passengers in London taxi accidents: Authors' reply
Authors: P G Richards, H A Crockard
Journal: BMJ (1986)

referenced with a colleague or senior member of the nursing staff.Further evidence of incom- petence must be presented to senior colleagues.The options open to them will be explained by the personnel officer of the district and may include secondment to a more supervised post for the remainder of this man's contract.It is most important for the registrar to realise that he is not alone in this dilemma.Many of us have faced it and I have had to persuade both doctors and paramedical staff to reconsider their career plans in the light of such findings of incompetence.
Silk Fibroin Hydrogels: Enhanced Osteogenesis of Bone Marrow‐Derived Mesenchymal Stem Cells by a Functionalized Silk Fibroin Hydrogel for Bone Defect Repair (Adv. Healthcare Mater. 3/2019)
Authors: Yufei Yan, Baochang Cheng, Kaizhe Chen, Wenguo Cui, Jin Qi, Xinming Li, Lianfu Deng
Journal: Advanced Healthcare Materials (2019)

Manuscript number 1801043 by Jin Qi, Xinming Li, and co-workers illustrates that the integration of silk fibroin proteins from domesticated silkworms (B. mori) and a small peptide gelator (NapFFRGD) can work as an effective means for the generation of a novel bioactive hydrogel with high biocompatibility, slow biodegradation rate, and good cell-adhesive properties, compared to other traditional methods. More importantly, because of the presence of RGD ligands within the gel matrix, the resulting hydrogel is capable of forming favorable microenvironments, and inherently inducing the differentiation of bone marrow-derived mesenchymal stem cells for bone regeneration.
GP at Hand: commissioning group plans to cut extended hours at other practices
Authors: Gareth Iacobucci
Journal: BMJ (2019)

The west London clinical commissioning group (CCG) hosting Babylon’s GP at Hand service is planning to drastically cut the number of extended hours appointments available to patients from other local practices because of funding pressures.

From this April, practices in Hammersmith will be forced to reduce the number of morning, evening, and weekend appointments they offer. Some practices may lose two thirds of their extended appointment slots and tens of thousands of pounds, The BMJ has learnt.

The plans, which will go out to consultation this month, would replace the existing local enhanced service for extended hours with the cheaper national directed enhanced service, saving the CCG almost £600 000. This would reduce the total number of GP appointments available outside core …